Table 4.

Summary of Y-90 dose to tumors

A.
Patient (dose)*DiagnosisLocationVolume (cc)Y-90 AUC (mCi*hr/mCi)Y-90 Dose (rad/mCi)Delivered Dose (rad)Response
1 (45)ColorectalPerihilar10.30.16231.2989.7Stable
Pancreas203.70.6486.3200.1Stable
Periclavicular9.10.0296.4202.0
2 (60)ColorectalLeft lingular0.40.076392.911079.1Progression
Perihilar0.30.054403.111368.7Progression
Right hepatic149.2whole liver dose37.71064.1Stable
3 (90)NSCLCMediastinum14.10.873122.53392.2Progression
4 (120)ColorectalSubcarinal36.10.64935.73502.4Progression
Right lung17.20.15217.61728.1Stable
Left lung3.60.17998.99700.3Partial response
5 (120)NSCLCRight lower lobe179.62.12123.4552.9Stable
6 (135)ColorectalMesenteric node4.00.517253.47704.2Partial response
Subcarinal3.40.07946.51414.8Stable
7 (135)TeratomaLeft lung688.33.72910.8433.2Stable
8 (150)ColorectalPerihilar12.70.32150.01795.7Progression
9 (150)ColorectalRight hepatic470.5whole liver dose40.41005.1Stable
Paratracheal3.50.293164.44093.9Progression
10 (150)ColorectalLung nodule0.50.192740.0191667.0Stable
Right liver89.53.11569.01788.5Stable
B. Summary of Y-90 dose to tumors

Volume (cc)
Y-90 dose (rad/mCi)
Delivered dose (rad)
Average99.8134.24272.8
STD184.4190.65172.5
Maximum688.3740.019167.0
Median12.746.51788.5
  • Abbreviations: NSCLC, non−small cell carcinoma; STD, standard.

  • * Gemcitabine dose level, g/m2.

  • By computed tomography scan as noted.

  • By nuclear medicine scan.